Eli Lilly
LLY | NYSE
$1,434.26
-$9.24 (-0.64%)
At close: Nov 16, 2026, 3:59 PM ET
$1,436.00
+$1.74 (+0.12%)
After-hours:
Nov 16, 2026, 7:59 PM ET
Eli Lilly Company Profile
Company profile explainedCompany Profile
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Key Executives
| Name | Position |
|---|---|
| David A. Ricks | Chairman, Chief Executive Officer & President |
| Eric Dozier | Executive Vice President & Chief People Officer |
| Lucas E. Montarce | Executive Vice President & Chief Financial Officer |
| Anat Hakim | Executive Vice President, General Counsel & Secretary |
| Daniel Skovronsky | Chief Scientific & Product Officer and President of Lilly Research Laboratories |
| Diogo Rau | Executive VP and Chief Information & Digital Officer |
| Donald A. Zakrowski | Senior Vice President of Finance & Chief Accounting Officer |
| Ilya Yuffa | Executive VP and President of Lilly USA & Global Customer Capabilities |
| Jacob S. Van Naarden | Executive VP, President of Lilly Oncology & Head of Corporate Business Development |
| Michael Czapar | Senior Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 10-Q | Quarterly Report |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 22, 2026 | 3 | Filing |
| Oct 20, 2026 | 4 | Filing |
| Oct 20, 2026 | 4 | Filing |
| Oct 20, 2026 | 4 | Filing |
| Oct 20, 2026 | 4 | Filing |
| Oct 19, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 16, 2026 | SC 13D | Filing |
| Oct 08, 2026 | 3 | Filing |
Eli Lilly
| Country | United States |
| IPO Date | Jun 1, 1972 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 50,000 |
| CEO | David A. Ricks |
Contact Details
Lilly Corporate Center Indianapolis,
Indiana 46285 United States
Stock Details
| Ticker Symbol | LLY |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000059478 |
| CUSIP Number | 532457108 |
| ISIN Number | US5324571083 |
| SIC Code | 2834 |
Recent News
- 12 hours ago / gurufocus.comLilly Bets Up to $1.5 Billion on Calytrix's Preclinical Antibody
- 13 hours ago / wsj.comEli Lilly to Buy Calytrix Bio for Up to $1.5 Billion
- 15 hours ago / zacks.comEli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
- 1 day ago / fool.comPrediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027
- 3 days ago / reuters.comMapping the Market: Eli Lilly shares ready to rally again
- 4 days ago / prnewswire.comLilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020
- 4 days ago / fool.comNvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on It
- 4 days ago / reuters.comChina approves Eli Lilly's weight loss pill orforglipron
- 5 days ago / benzinga.comEXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat
- 5 days ago / prnewswire.comNew Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
Add to Watchlist
Select watchlists to add or remove LLY